Want to join the conversation?
Drug maker $BMY announced the early stop of its CheckMate-141 study in patients with head and neck cancer, which is the fifth early study stop with Opdivo. In 2015, three of the company's key trials with Opdivo were stopped early because of a survival advantage versus the previous standard of care. Opdivo is now approved in 46 countries.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.